Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Q1 FY27 Earnings Presentation
11 slides from Curvebeam Ai's earnings presentation, Oct 21, 2026
Slide 1: Q1 FY27 Quarterly Company Call
personal use only Q1 FY27 QUARTERLY COMPANY CALL 21 October 2026
Slide 2: Disclaimer
DISCLAIMER personal use only Introduction Forward looking statements THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, The information given in this presentation is given for illustrative purposes only and should not be relied upon as DIRECTLY OR INDIRECTLY, IN
Slide 3: Q1 FY27 Key Highlights
Q1 FY27 KEY HIGHLIGHTS personal use only • Purchase orders (POs) secured during Q1 FY27 totaled five (5) devices, all HiRise™ marking the strongest Q1 sales result to date • Company received U.S. FDA 510(k) clearance for Bone Mineral Density (BMD) for multidetector CT (MDCT) • Following successful r
Slide 4: Key Highlights
Q1 FY27 KEY HIGHLIGHTS personal use only • The Company continues to advance the validation pathway for HiRise™ datasets with a major robotic-assisted surgery system • Latest trial scans have demonstrated that HiRise™ data could be processed successfully through applicable software workflows, with mo
Slide 5: Cash Analysis
Q1 FY27 CASH ANALYSIS personal use only • Company raised a total of A$7.35 m through a combination of capital raisings, comprising a A$5.0 m placement (A$0.02/share), an SPP raising of A$0.6 m (A$0.018/share), and a Shortfall Offer and placement raising of an additional A$1.75 m (A$0.018/share) • Du
Slide 6: Purchase Orders Analysis
Q1 FY27 PURCHASE ORDERS ANALYSIS personal use only TM • Receipts Q1 FY27 were A$1.80m, down 30% from A$2.58m in Q4 FY26, up 31% from comparative quarter in FY26 A$1.37m • CVB carried A$4.2m of purchase orders & receivables into Q1 & carries A$4.9m into Q2. Revenue recognition cycle of CVB ranges fro
Slide 7: BoneVue BMD MDCT FDA Cleared
BONEVUE BMD MDCT FDA CLEARED personal use only 2nd Step Multidetector CT (MDCT) clearance • September, CurveBeam AI received U.S. FDA (FDA) 510(k) clearance for its first product for CT-based Bone Mineral Density (BMD) for multidetector CT (MDCT) scans. • Following feedback from the FDA during the 5
Slide 8: Enhanced HiRise Project for Robotic Aided Surgical Systems
ENHANCED HIRISE™ PROJECT FOR ROBOTIC personal use only AIDED SURGICAL SYSTEMS • CurveBeam AI has now implemented significant product improvements, including enhanced patient stabilisation methods & software-based anatomical alignment refinements designed to meet the clinical and technical objectives
Slide 9: Robotic Market Dynamics – Drives CT Dependence
ROBOTIC MARKET DYNAMICS – DRIVES CT DEPENDENCE personal use only 1. Robotic system adoption for orthopedics continues at a steady pace with ~ 25% of US operating rooms having access to a robot - Source Global Data 2023 2. Stryker MAKO, J&J VELYS, Zimmer ROSA and S&N CORI – held 85% of the market - S
Slide 10: Definitions
DEFINITIONS personal use only CurveBeam AI’s key metrics are defined and interpreted as follows: • Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time. • Receipts from customers – any cash
Slide 11: Questions
personal use only QUESTIONS 11 I N V E S T O R P R E S E N T A T I O N